Hikma Pharmaceuticals Overview
- Founded
-
1978
- Status
-
Public
- Employees
-
8,700
- Stock Symbol
-
HIK
- Investments
-
21
- Share Price
-
$19.35
- (As of Monday Closing)
Hikma Pharmaceuticals General Information
Description
Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
LON
Primary Office
- 1 New Burlington Place
- London W1S 2HR
- England, United Kingdom
+44 020 0000 0000
Hikma Pharmaceuticals Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $19.35 | $19.51 | $0.40 - $36.32 | $4.26B | 220M | 883K | $1.51 |
Hikma Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 4,728,277 | 7,531,560 | 8,410,786 | 6,688,814 |
| Revenue | 2,550,000 | 2,553,000 | 2,341,000 | 2,207,000 |
| EBITDA | 699,000 | 766,000 | 742,000 | 653,000 |
| Net Income | 346,000 | 421,000 | 431,000 | 486,000 |
| Total Assets | 4,747,000 | 4,372,000 | 4,135,000 | 3,930,000 |
| Total Debt | 1,551,000 | 846,000 | 932,000 | 685,000 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Hikma Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hikma Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded
Pharmaceuticals
London, United Kingdom
8,700
As of 2022
00000
000000000
00000
000 00
d tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercita
000000000000000
Ramapo, NY
0000
As of 0000
000.00
0.000
0000-00-00
000000&0
000.00
000 00
veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aut
000000000000000
Mumbai, India
00000
As of 0000
000000000000
Add Comparison
Hikma Pharmaceuticals Competitors (5)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Par Pharmaceutical Companies | Formerly PE-Backed | Ramapo, NY | 0000 | 000.00 | 000000&0 | 000.00 |
| 000 00000000000000 | Corporation | Mumbai, India | 00000 | 000000000000 | ||
| 000000 | Corporation | Carros, France | 0000 | 00000000 | ||
| 00000000 | Corporation | Basel, Switzerland | 000000 | 000000000000 | ||
| 000000 00000000000 | Corporation | Tokyo, Japan | 00000 | 00000000 |
Hikma Pharmaceuticals Patents
Hikma Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20100125051-A1 | Parenteral formulations comprising sugar-based esters and ethers | Granted | 19-Nov-2008 | 000000000 | 00 |
| US-8541360-B2 | Parenteral formulations comprising sugar-based esters and ethers | Active | 19-Nov-2008 | 000000000 | 00 |
Hikma Pharmaceuticals Executive Team (28)
Hikma Pharmaceuticals Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000000 0000000 | Hikma Pharmaceuticals | Board Member | 000 0000 |
| 000000 0000 | Self | Board Member | 000 0000 |
| 0000 0000000000 | Hikma Pharmaceuticals | Board Member | 000 0000 |
| 00000 00000000 | Hikma Pharmaceuticals | Executive Vice Chairman and President of MENA | 000 0000 |
| 00000000 000 00-00000 | Self | Non-Executive Director | 000 0000 |
Hikma Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Hikma Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Hikma Pharmaceuticals Investments & Acquisitions (21)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 | 21-Apr-2022 | 0000000000 | 00000 | Pharmaceuticals | 00000000 |
| 00000000 0000 | 03-Feb-2022 | 0000000000 | 000.00 | Pharmaceuticals | 0000 0000 |
| 000000 000000 | 02-Jan-2019 | 0000000000 | 0000.00 | Medical Supplies | 0000 0000 |
| 000000 000000 | 29-Feb-2016 | 0000000000 | 00.000 | Pharmaceuticals | 0000 0000 |
| EIMC United Pharmaceuticals | 08-Sep-2015 | Merger/Acquisition | 0000 | Drug Discovery |
Hikma Pharmaceuticals Subsidiaries (5)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Hikma Ventures | Corporate Venture Capital | London, United Kingdom | 2015 |
| 0000000000 | Pharmaceuticals | Carlsbad, CA | 0000 |
| 00000000000 | Distributors (Healthcare) | Grafelfing, Germany | 0000 |
| 0000 0000000000000 | Pharmaceuticals | Al Salt, Jordan | 0000 |
| 0000000000 | Pharmaceuticals | Casablanca, Morocco | 0000 |
Hikma Pharmaceuticals Exits (3)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000000000000 00 | 17-Sep-2014 | 000000000 00000 00 | Completed |
|
|
| 000 00000 00000000 | 15-Jul-2014 | 000000000000000000 | 00000 | Completed |
|
| Unimark Remedies | 15-Apr-2011 | Corporate | 000.00 | Completed |